Clinical Cancer Research

AI summary · may contain errors

SPROUT consensus guidelines standardize DNA/RNA next-generation sequencing and methylation profiling timing for children with pediatric solid tumors, based on 41 included studies.

AI summary · may contain errors

WCDD115 radiosensitizes NRF2-competent head and neck squamous cell carcinoma by suppressing one-carbon metabolism and nucleotide biosynthesis, enhancing radiation-induced DNA damage.

AI summary · may contain errors

In 32 patients with HR+/HER2+ advanced breast cancer and measurable brain metastases, confirmed CNS-ORR reached 58.6% (95% CI 40.7–74.5) on palbociclib, fulvestrant, trastuzumab, and pyrotinib.

AI summary · may contain errors

MTAP loss is detected in 17% of 243 non-small cell lung cancers, including 24% of stage 4 driver-positive tumors, highlighting a frequent, actionable biomarker.

AI summary · may contain errors

BRCA1 loss is linked to mitochondrial dysfunction, mtDNA instability, oxidative stress, and inflammatory remodeling, creating therapeutic vulnerabilities beyond homologous recombination deficiency.

AI summary · may contain errors

Short-course dabrafenib plus trametinib restored iodine uptake within 2 weeks in 6 of 9 (67%) radioiodine-treated patients with MAPK-driven radioiodine-refractory thyroid carcinoma.

AI summary · may contain errors

An eight-metabolite plasma panel predicts future bladder cancer risk in UK Biobank with AUC 0.98 in a held-out test and 0.92 in validation.

AI summary · may contain errors

MTAP loss in unresectable malignant pleural mesothelioma is linked to higher ICI response rates and immune features, including increased CD8+ T-cell infiltration and T-cell receptor diversity in the C-CAT cohort.

AI summary · may contain errors

Dose interruptions of four or more consecutive days in US FDA trial populations of NSCLC with EGFR mutations are more often linked to higher progression or death risk than dose reductions.

AI summary · may contain errors

Stk11 loss in Kras-mutant murine lung models promotes NETosis via the complement C5a–C5aR1 axis, creating an immunosuppressive TME that resists PD-1/PD-L1 blockade.

AI summary · may contain errors

In curatively treated esophageal cancer patients, ultrasensitive MAESTRO ctDNA testing detected occult disease earlier, with 60% of ctDNA-positive samples below 100 ppm.

AI summary · may contain errors

A composite biomarker combining membranous Nectin-4 expression with NECTIN4 gene amplification predicts response to enfortumab vedotin in muscle-invasive or metastatic urothelial cancer.

AI summary · may contain errors

High baseline circulating γδ T cells and early expansion of circulating CD8+PD-1+ T cells predict better outcomes with atezolizumab-bevacizumab in first-line hepatocellular carcinoma.

AI summary · may contain errors

Panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma achieved a 53.9% objective response rate, including 15.4% complete responses, across 26 patients.

AI summary · may contain errors

Ulixertinib showed no objective responses (ORR 0%) in 34 pancancer patients with BRAF fusions or non-V600E/non-V600K BRAF mutations.

AI summary · may contain errors

Intratumoral MEDI1191 plus intravenous durvalumab showed no dose-limiting toxicities in 61 patients with advanced solid tumors, with an objective response rate of 9.8%.

AI summary · may contain errors

EMB-01 given weekly at 1,600 mg showed a confirmed objective response rate of 12.5% in 48 heavily pretreated metastatic colorectal cancer patients.

AI summary · may contain errors

Neoadjuvant nivolumab plus carboplatin and paclitaxel in stage III–IV HPV-negative SCCHN and stage II–III HPV-positive oropharyngeal SCCHN achieved a 45% primary-site pCR.

AI summary · may contain errors

Tinengotinib showed clinical benefit in 27.0% of evaluable patients with advanced solid tumors, with antitumor activity strongest at 10 mg and 12 mg once daily.

AI summary · may contain errors

Beta-adrenergic receptor signaling is linked to immune suppression in the tumor microenvironment, while beta-blocker use is associated with survival benefits across cancers in studies totaling over 600,000 patients.

AI summary · may contain errors

In a single-center phase II trial in 42 patients with advanced biliary cancer, pembrolizumab plus GM-CSF achieved a confirmed ORR of 12% (95% CI, 4–26).

AI summary · may contain errors

Botensilimab plus balstilimab produced an objective response rate of 21% in 123 patients with microsatellite-stable metastatic colorectal cancer without active liver metastases, with 36-month OS of 33%.

AI summary · may contain errors

SEE-TC, a deep learning system for circulating tumor cell imaging, segments and phenotypes cells at human-level accuracy across 8.5 million cells from 3,386 blood samples.

AI summary · may contain errors

Neoadjuvant nivolumab plus carboplatin and paclitaxel in locally advanced, resectable head and neck squamous cell carcinoma improves pathologic response rates versus chemotherapy or immunotherapy alone.

AI summary · may contain errors

FGFR2b, an alternatively spliced isoform of FGFR2, is a prevalent membrane cell-surface target in intrahepatic cholangiocarcinoma, present in 88.6% (institutional) and 88.2% (TCGA).

AI summary · may contain errors

[225Ac]Ac-Macropa-M16AB achieved complete remissions in MUC-16-positive ovarian and pancreatic ductal adenocarcinoma patient-derived xenografts, with 100% sustained CRs in high/medium expressers.